New Zealand markets open in 4 minutes

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.0650+0.0550 (+1.37%)
As of 03:56PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close4.0100
Bid4.0300 x 900
Ask4.0400 x 1200
Day's range3.8500 - 4.1000
52-week range3.5800 - 39.4900
Avg. volume2,244,569
Market cap247.558M
Beta (5Y monthly)0.77
PE ratio (TTM)N/A
EPS (TTM)-11.6890
Earnings date21 Feb 2022 - 25 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est12.36
  • GlobeNewswire

    Esperion Provides Preliminary Fourth Quarter 2021 Financial Results and CLEAR Outcomes Program Update

    – Unprecedented CLEAR Outcomes Trial Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Accumulation in 2H 2022; Achieved 85% MACE Accumulation in December – – Fourth-quarter 2021 U.S. Net Product Revenue Estimated Between $12.0 to $12.5 Million – – Company Reiterates Full-Year 2022 Operating Expense Guidance of $220 to $240 Million – ANN ARBOR, Mich., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced preliminary, unaudited fourth-quarter 2021 financial res

  • GlobeNewswire

    Esperion to Participate in Upcoming Virtual J.P. Morgan 40th Annual Healthcare Conference

    ANN ARBOR, Mich., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming virtual J.P. Morgan 40th Annual Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. Eastern Time. Event:J.P. Morgan 40th Annual Healthcare ConferenceDate:Thursday, January 13, 2022Format:Presentation and 1:1 MeetingsTime:10:30 a.m. ET Live audio webcasts of these events can be accessed on the investor re

  • Simply Wall St.

    What Type Of Shareholders Own The Most Number of Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares?

    Every investor in Esperion Therapeutics, Inc. ( NASDAQ:ESPR ) should be aware of the most powerful shareholder groups...